DYADIC INTERNATIONAL INC 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32513 DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 State or Other Jurisdiction of Incorporation or Organization I.R.S. Employer Identification No. 1044 North U.S. Highway One , Suite 201 Jupiter , Florida 33477 Address of Principal Executive Offices Zip Code (561) 743-8333 Registrant’s Telephone Number, Including Area Code N/A Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share DYAI The NASDAQ Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ The number of shares outstanding of the registrant’s Common Stock as of August 12, 2025 was 36,187,798 . TABLE OF CONTENTS Page PART I FINANCIAL INFORMATION 3 Item 1. Financial Statements 3 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3. Quantitative and Qualitative Disclosures about Market Risk 30 Item 4. Controls and Procedures 30 PART II OTHER INFORMATION Item 1. Legal Proceedings 31 Item 1A. Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 32 Signatures 33 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q (“Quarterly Report”) contains forward-looking statements within the meaning of the federal securities laws, particularly under Item 2 “Management’s Discussion and Analysis.” All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding industry prospects, future business, future results of operations or financial condition, future liquidity and capital resources, our ability to implement our agreements with third parties, management strategies, and our competitive position. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic’s control. These factors include, but are not limited to (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (x) intellectual property risks; (xi) our ability to comply with the listing standards of the Nasdaq Stock Market LLC; and (xii) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in this Quarterly Report and in our annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 26, 2025 (the “Annual Report”). We caution you that the foregoing list of important factors is not exclusive. Any forward-looking statements are based on our beliefs, assumptions, and expectations of future performance, considering the information currently available to us. Before investing in our common stock, investors should carefully read the information set forth under the caption “Risk Factors” and elsewhere in this Quarterly Report, in our Annual Report and in our other SEC filings, which could have a material effect on our business, results of operations and financial condition. The forward-looking statements contained in this Quarterly Report are made only as of the date hereof, and except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations. 2 PART I Item 1. Financial Statements DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) (Audited) Assets Current assets: Cash and cash equivalents $ 2,140,899 $ 6,506,750 Short-term investment securities 2,842,419 2,756,577 Restricted cash and cash equivalents, current 1,588,384 — Interest receivable 34,736 24,248 Accounts receivable 715,317 237,027 Prepaid expenses and other current assets 84,984 303,066 Total current assets 7,406,739 9,827,668 Non-current assets: Long-term investment securities 409,670 — Restricted cash and cash equivalents, noncurrent 245,147 — Operating lease right-of-use asset, net 65,961 92,211 Other assets 10,529 10,396 Total assets $ 8,138,046 $ 9,930,275 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 738,794 $ 482,320 Accrued expenses 929,850 970,462 Deferred research and development obligations 1,833,531 833,813 Operating lease liability, current portion 57,577 54,249 Accrued interest 80,000 80,000 Accrued interest- related party 21,800 27,173 Total current liabilities 3,661,552 2,448,017 Non-current liabilities: Convertible notes, net of issuance costs 3,930,170 3,911,471 Convertible notes, net of issuance costs - related party 1,070,971 1,065,876 Operating lease liability, net of current portion 5,054 34,621 Total liabilities 8,667,747 7,459,985 Commitments and contingencies (Note 5) - - Stockholders’ equity: Preferred stock, $ .0001 par value: Authorized shares - 5,000,000 ; none issued and outstanding — — Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding — — Common stock, $ .001 par value: Authorized shares - 100,000,000 ; issued shares - 42,389,300 and 42,089,301 , outstanding shares - 30,135,798 and 29,835,799 as of June 30, 2025, and December 31, 2024, respectively 42,390 42,090 Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 42,389,300 and 42,089,301, outstanding shares - 30,135,798 and 29,835,799 as of June 30, 2025, and December 31, 2024, respectively 42,390 42,090 Additional paid-in capital 108,265,657 107,444,595 Treasury stock, shares held at cost - 12,253,502 ( 18,929,915 ) ( 18,929,915 ) Accumulated deficit ( 89,907,833 ) ( 86,086,480 ) Total stockholders’ equity ( 529,701 ) 2,470,290 Total liabilities and stockholders’ equity $ 8,138,046 $ 9,930,275 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) 2025 2024 2025 2024 Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues: Research and development revenue $ 213,449 $ 385,896 $ 396,549 $ 720,513 Grant revenue 503,181 — 713,653 — License and milestone revenue 250,000 — 250,000 — Total revenue 966,630 385,896 1,360,202 720,513 Costs and expenses: Costs of research and development revenue 148,457 301,956 274,937 445,911 Costs of grant revenue 465,134 — 636,312 — Research and development 629,379 515,629 1,124,358 1,038,352 General and administrative 1,436,630 1,607,756 3,032,968 3,396,350 Foreign currency exchange loss 16,098 3,146 23,170 8,049 Total costs and expenses 2,695,698 2,428,487 5,091,745 4,888,662 Loss from operations ( 1,729,068 ) ( 2,042,591 ) ( 3,731,543 ) ( 4,168,149 ) Other income (expense): Interest income 49,127 138,471 137,585 225,914 Gain on sale of Alphazyme — — — 60,977 Interest expense ( 89,456 ) ( 88,634 ) ( 178,699 ) ( 110,273 ) Interest expense - related party ( 24,377 ) ( 52,469 ) ( 48,696 ) ( 63,288 ) Interest expense ( 24,377 ) ( 52,469 ) ( 48,696 ) ( 63,288 ) Total other income (expense), net ( 64,706 ) ( 2,632 ) ( 89,810 ) 113,330 Net loss $ ( 1,793,774 ) $ ( 2,045,223 ) $ ( 3,821,353 ) $ ( 4,054,819 ) Basic and diluted net loss per common share $ ( 0.06 ) $ ( 0.07 ) $ ( 0.13 ) $ ( 0.14 ) Basic and diluted weighted-average common shares outstanding 30,102,324 29,291,259 30,071,285 29,085,696 The accompanying notes are an integral part of these unaudited consolidated financial statements. 4 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS ’ EQUITY (Unaudited) Shares Amount Shares Amount Capital Deficit Total Six Months Ended June 30, 2025 Common Stock Treasury Stock Additional Paid-In Accumulated Shares Amount Shares Amount Capital Deficit Total January 1, 2025 42,089,301 $ 42,090 ( 12,253,502 ) $ ( 18,929,915 ) $ 107,444,595 $ ( 86,086,480 ) $ 2,470,290 Stock-based compensation expense — — — — 225,030 — 225,030 Issuance of common stock upon vesting of restricted stock units 250,964 251 — — 231,370 — 231,621 Issuance of common stock upon exercise of stock options 27,483 27 — — 24,222 — 24,249 Net loss — — — — — ( 2,027,579 ) ( 2,027,579 ) March 31, 2025 42,367,748 $ 42,368 ( 12,253,502 ) $ ( 18,929,915 ) $ 107,925,217 $ ( 88,114,059 ) $ 923,611 Stock-based compensation expense — — — — 340,462 — 340,462 Issuance of common stock upon vesting of restricted stock units 21,552 22 — — ( 22 ) — — Net loss — — — — — ( 1,793,774 ) ( 1,793,774 ) June 30, 2025 42,389,300 $ 42,390 ( 12,253,502 ) $ ( 18,929,915 ) $ 108,265,657 $ ( 89,907,833 ) $ ( 529,701 ) Six Months Ended June 30, 2024 Common Stock Treasury Stock Additional Paid-In Accumulated Shares Amount Shares Amount Capital Deficit Total January 1, 2024 41,064,563 $ 41,065 ( 12,253,502 ) $ ( 18,929,915 ) $ 105,044,756 $ ( 80,277,321 ) $ 5,878,585 Stock-based compensation expense — — — — 306,478 — 306,478 Issuance of common stock upon vesting of restricted stock units 375,753 376 — — 339,959 — 340,335 Net loss — — — — — ( 2,009,596 ) ( 2,009,596 ) March 31, 2024 41,440,316 $ 41,441 ( 12,253,502 ) $ ( 18,929,915 ) $ 105,691,193 $ ( 82,286,917 ) $ 4,515,802 Balance 41,440,316 $ 41,441 ( 12,253,502 ) $ ( 18,929,915 ) $ 105,691,193 $ ( 82,286,917 ) $ 4,515,802 Stock-based compensation expense — — — — 297,603 — 297,603 Issuance of common stock upon vesting of restricted stock units 61,793 62 — — ( 62 ) — — Issuance of common stock upon exercise of stock options 5,569 6 — — ( 6 ) — — Issuance of common stock upon settlement of convertible debt 223,463 223 — — 399,777 — 400,000 Net loss — — — — — ( 2,045,223 ) ( 2,045,223 ) June 30, 2024 41,731,141 $ 41,732 ( 12,253,502 ) $ ( 18,929,915 ) $ 106,388,505 $ ( 84,332,140 ) $ 3,168,182 Balance 41,731,141 $ 41,732 ( 12,253,502 ) $ ( 18,929,915 ) $ 106,388,505 $ ( 84,332,140 ) $ 3,168,182 The accompanying notes are an integral part of these unaudited consolidated financial statements. 5 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) 2025 2024 Six Months Ended June 30, 2025 2024 Cash flows from operating activities Net loss $ ( 3,821,353 ) $ ( 4,054,819 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense 565,492 604,081 Amortization of held-to-maturity securities, net ( 15,996 ) ( 27,699 ) Amortization of debt issuance costs 23,794 26,717 Gain from the sale of investment in Alphazyme — ( 60,977 ) Foreign currency exchange loss (gain), net 23,170 8,049 Changes in operating assets and liabilities: Interest receivable ( 10,488 ) ( 18,077 ) Accounts receivable ( 471,860 ) 210,725 Prepaid expenses and other current assets 218,050 201,073 Operating lease assets and liabilities 11 870 Accounts payable 224,080 ( 224,307 ) Accrued expenses 191,009 152,800 Accrued interest — 80,000 Accrued interest - related party ( 5,373 ) 32,000 Deferred research and development obligation 999,718 ( 7,790 ) Net cash used in operating activities ( 2,079,746 ) ( 3,077,354 ) Cash flows from investing activities Purchases of held-to-maturity investment securities ( 4,560,278 ) ( 4,734,528 ) Proceeds from maturities of investment securities 4,080,762 1,546,000 Proceeds from the sale of investment in Alphazyme — 60,977 Net cash used in investing activities ( 479,516 ) ( 3,127,551 ) Cash flows from financing activities Proceeds from exercise of stock 24,249 — Proceeds from issuance of convertible notes, net of issuance costs — 3,882,884 Proceeds from issuance of convertible notes, net of issuance costs - related party — 1,941,442 Net cash provided by financing activities 24,249 5,824,326 Effect of exchange rate changes on cash 2,693 ( 1,051 ) Net decrease in cash, cash equivalents, and restricted cash and cash equivalents ( 2,532,320 ) ( 381,630 ) Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period 6,506,750 6,515,028 Cash, cash equivalents, and restricted cash and cash equivalents at end of period $ 3,974,430 $ 6,133,398 Reconciliation of cash, cash equivalents, and restricted cash and cash equivalents to the consolidated balance sheets Cash and cash equivalents $ 2,140,899 $ 6,133,398 Restricted cash and cash equivalents, current 1,588,384 — Restricted cash and cash equivalents, noncurrent 245,147 — Total cash, cash equivalents, and restricted cash and cash equivalents $ 3,974,430 $ 6,133,398 Supplemental cash flow information Vesting of restricted stock units $ 269,100 $ 439,085 Conversion of convertible notes $ — $ 400,000 Cash paid for interest $ 208,973 $ 34,844 The accompanying notes are an integral part of these unaudited consolidated financial statements. 6 Notes to Consolidated Financial Statements Note 1: Organization and Summary of Significant Accounting Policies Description of Business Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company headquartered in Jupiter, Florida, with operations in the U.S. and the Netherlands. We aim to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. Our proprietary platforms—Dapibus™ and C1—are designed for rapid, cost-effective, and flexible production of high-value proteins, enabling partners to reduce development timelines and manufacturing costs. While Dyadic’s primary focus is on non-therapeutic applications, both platforms retain the capability to produce biologics, such as vaccines and therapeutic proteins, for external partners. DBA Name Change Update Effective on August 1, 2025, we are doing business as Dyadic Applied BioSolutions (as previously announced on July 2, 2025). This rebranding initiative marks a strategic transition from a research-driven organization to a commercially focused enterprise. The new name and visual identity better reflect the emphasis on delivering applied biotechnology solutions through our patented and proprietary C1 and Dapibus™ gene expression platforms. This underscores our focus on commercializing high-value, non-therapeutic proteins in the life sciences, food, nutrition and industrial bioprocessing sectors. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics, enabling faster time to revenue, broader market reach, and long-term supply agreements. Our recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, such as with the Gates Foundation, underscore our strategic shift to revenue-focused bioprocessing protein platforms from therapeutic and vaccine development. Liquidity and Capital Resources In accordance with FASB Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements – Going Concern (“Topic 205-40”), management is required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the issuance date of the Company’s condensed interim financial statements. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its C1 and Dapibus TM microbial protein production platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its third-party collaborators and licensees. The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval, commercialization, and subsequent revenue generation or through the sublicensing of the Company’s technologies and products, and its ability to raise capital to finance these developmental efforts. On March 8, 2024, the Company issued an aggregate principal amount of $ 6.0 million of its 8.0 % Senior Secured Convertible Promissory Notes due March 8, 2027 (the “Convertible Notes”) in a private placement. The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company’s outstanding common stock, (collectively, the “Purchasers”). The net proceeds from the sale of the Convertible Notes, after deducting offering expenses, were $ 5,824,326 . The Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes. The Convertible Notes are senior, secured obligations of Dyadic and its affiliates, and interest is payable quarterly in cash on the principal amount equal to 8 % per annum. The Convertible Notes will mature on March 8, 2027 (the “Maturity Date”), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes can be converted into shares of Dyadic’s common stock, par value $ 0.001 per share (the “Common Stock”), at the option of the holders of the Convertible Notes (the “Noteholders”) at any time prior to the Maturity Date. 7 On October 4, 2024, the Company entered into an amendment (the “Amendment”) to the Convertible Notes. Pursuant to the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company’s common stock is $ 1.40 per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fall on any of the 26, 29 and 32-month anniversaries of the original issue date of the Convertible Notes. During the year ended December 31, 2024, $ 910,000 of the Convertible Notes were converted into 556,623 shares of Common Stock. For more information regarding the Convertible Notes, including the covenants related thereto, see Note 4 to the Consolidated Financial Statements. On May 1, 2025, the Company entered into a second amendment (the “Second Amendment”) to the Convertible Notes. Pursuant to the Second Amendment, the Redemption Date (as defined in the Second Amendment) will now fall on December 1, 2026. The Convertible Notes contain customary covenants, and the Securities Purchase Agreement relating to the Convertible Notes also contains certain affirmative and negative covenants (including, without limitation, restrictions on our ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions). The Company was in compliance with its covenants with respect to the Convertible Notes as of June 30, 2025. On November 16, 2024, Dyadic entered into an agreement with the Gates Foundation (the “Gates Foundation”, formerly known as the Bill & Melinda Gates Foundation) relating to a grant in the amount of $ 3,092,136 awarded from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company’s C1 platform to provide globally accessible treatment options for underserved populations (the “Gates Foundation Grant”). Funds received in advance that have not been spent are recorded as restricted cash and cash equivalents in the Company’s consolidated balance sheets. On March 20, 2025, the Company received a funding award from Coalition for Epidemic Preparedness (“CEPI”) to advance Dyadic’s C1 platform through a $ 4.5 million grant through Fondazione Biotecnopolo di Siena (“FBS”) to accelerate recombinant protein vaccine development and manufacturing. The funding will support antigen design, cell line development, optimization, characterization, and scale-up to cGMP manufacturing. If successful, the next phase will focus on selecting a CEPI-priority pathogen antigen. Dyadic, as a subcontractor, will receive up to $ 2.4 million of the total grant funding. On July 30, 2025, the Company entered into an underwriting agreement with Craig-Hallum Capital Group LLC, in its capacity as underwriter, relating to the issuance and sale (the “Offering”) of 6,052,000 shares of the Company’s Common Stock. The public offering price in the Offering was $ 0.95 per share of Common Stock. The closing of the Offering occurred on August 1, 2025. The net proceeds to the Company from the Offering were approximately $ 5.3 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes, such as product development, sales and marketing. The Company expects its existing cash, cash equivalents, restricted cash and cash equivalents and its short term investment securities, totaling approximately $ 6.9 million as of June 30, 2025, together with the capital raised from the Offering of approximately $ 5.3 million, will be sufficient to meet its operational, business, and other liquidity requirements for at least the next twelve (12) months from the date of issuance of the financial statements contained in this Quarterly Report. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. In the event our financing needs are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are not limited to, future public or private equity offerings, collaboration agreements, convertible notes or other debt instruments, and/or other means. Any amount raised may be used for the further development and commercialization of product candidates, and for other working capital purposes. There is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) as found in the Accounting Standards Codification (“ASC”), Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2024, included in our Annual Report. 8 In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. Segment Information Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The CODM is the Company’s senior management team that includes the Chief Executive Officer, President & Chief Operating Officer, and Chief Financial Officer. The Company views its operations as and manages its business in one operating segment, which is the business of developing and commercializing recombinant protein products using the Company’s proprietary microbial platforms, including C1 and Dapibus™. Segment information is further described in Note 8 to the consolidated financial statements included in this Quarterly Report on Form 10-Q. Use of Estimates The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Estimates inherent in the preparation of these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements. Concentrations and Credit Risk The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company currently deals with four reputable financial institutions and has not experienced any losses in those accounts. For the three months ended June 30, 2025 and 2024, the Company’s revenue was generated from eight and ten customers, respectively. For the six months ended June 30, 2025 and 2024, the Company’s revenue was generated from ten and thirteen customers, respectively. Significant customers are those that account for greater than 10% of the Company’s revenues. For the three months ended June 30, 2025 and 2024, three and four significant customers accounted for $ 794,615 or 58.4 % and $ 284,594 or 73.7 % of revenue, respectively. For the six months ended June 30, 2025 and 2024, four and five significant customers accounted for $ 1,101,653 or 80.9 % and $ 506,379 or 70.3 % of revenue, respectively. As of June 30, 2025 and December 31, 2024, accounts receivable was from seven and nine customers, of which, four and three customers accounted for $ 658,005 or 92.0 % and $ 158,416 or 66.9 % of total accounts receivable, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations. The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the three months ended June 30, 2025 and 2024, the Company had three and four customers outside of the United States (i.e., European customers) that accounted for $ 63,560 or 6.6 % and $ 105,932 or 27.5 % of revenue, respectively. For the six months ended June 30, 2025 and 2024, the Company had three and seven customers outside of the United States (i.e., European customers) that accounted for $ 111,893 or 8.2 % and $ 304,001 or 42.2 % of revenue, respectively. As of June 30, 2025 and December 31, 2024, the Company had three and four customers outside of the United States (i.e., European customers) that accounted for $ 304,548 or 42.6 % and $ 145,603 or 61.5 % of accounts receivable, respectively. The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the three months ended June 30, 2025 and 2024, two CROs accounted for $ 880,020 or 91.1 % and $ 597,696 or 96.5 % of total research services we purchased, respectively. For the six months ended June 30, 2025 and 2024, two CROs accounted for $ 1,363,447 or 85.9 % and $ 957,040 or 90.2 % of total research services we purchased, respectively. As of June 30, 2025 and December 31, 2024, two CROs accounted for $ 638,908 or 86.5 % and $ 284,166 or 58.9 % of accounts payable, respectively. The loss of one CRO or a combination of the Company’s CROs could adversely affect its operations. Cash and Cash Equivalents We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use. Investment Securities The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of each investment at the time of purchase and reevaluates the classifications at each balance sheet date. The Company classifies its investments in debt securities as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, net of allowance for credit losses if applicable, and adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. The Company measures expected credit losses on held to maturity debt securities on an individual security basis. The estimate of expected credit losses considers historical credit information from external sources. The impairment of the investment that is related to the credit loss, if any, is expensed in the period in which the event or change occurred. 9 The Company classifies its investments in money market funds as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of June 30, 2025 and December 31, 2024, all our money market funds were invested in U.S. Government money market funds, for which the risk of loss is minimal. As of June 30, 2025, and December 31, 2024, the Company did not have any investment securities classified as trading. Restricted Cash and Cash Equivalents Restricted cash and cash equivalents represent amounts subject to restrictions under an agreement with the Gates Foundation. These funds may need to be refunded and are limited to use as specified in the agreement. The restriction on these funds lapses as the Company fulfills its obligations under the agreement. Amounts expected to be used within the next twelve (12) months are classified as current. Accounts Receivable Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project. Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company’s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company’s evaluation of current and expected future economic conditions and changes in our customer collection trends. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. Management determined that no allowance for credit losses was required as of June 30, 2025, and December 31, 2024. Accounts receivable consist of the following: Schedule of Accounts Receivables June 30, 2025 December 31, 2024 (Unaudited) (Audited) Billed receivable $ 455,152 $ 173,993 Unbilled receivable 260,165 63,034 Accounts receivable $ 715,317 $ 237,027 Accounts Payable Accounts payable consist of the following: Schedule of Accounts Payable June 30, 2025 December 31, 2024 (Unaudited) (Audited) Research and development expenses $ 654,571 $ 340,698 Legal expenses — 68,420 Other 84,223 73,202 Accounts payable $ 738,794 $ 482,320 Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses June 30, 2025 December 31, 2024 (Unaudited) (Audited) Employee wages and benefits $ 349,187 $ 496,906 Research and development expenses 452,970 437,196 Legal expenses 110,833 25,000 Other 16,860 11,360 Accrued expenses $ 929,850 $ 970,462 Deferred Financing Costs Deferred financing costs represent costs incurred in connection with the issuance of debt instruments and equity financings. Deferred financing costs related to the issuance of debt are amortized over the term of the financing instrument using the effective interest method and are presented in the consolidated balance sheets as an offset against the related debt. Offering costs from equity financings are netted against the gross proceeds received from the equity financings. See Note 4 for the amortization amount. Revenue Recognition The Company has no products approved for sale. All our revenue to date has been research revenue from third-party collaborations and grants, as well as revenue from sublicensing agreements and collaborative arrangements, which may include upfront payments, options to obtain a license, payment for research and development services, milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest). Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) a locate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. 10 Under the input method, revenue will be recognized based on the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfil the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified, and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. Revenue related to grants: The Company receives grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations. However, most, if not all, of such grant revenues, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials. Revenue related to grants is presented on a gross basis on the Consolidated Statements of Operations. Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license. Customer options: If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate if such options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement. Milestone payments : At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of the product, the Company recognizes milestone payment by applying the accounting guidance for royalties. Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or a the royalty has been a located has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements. We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to a sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from the licensing agreement. Research and Development Costs Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects. Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, for the three and six months ended June 30, 2025 and 2024 were as follows: Schedule of Research and Development Costs 2025 2024 2025 2024 Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Outside contracted services $ 486,585 $ 395,188 $ 842,841 $ 783,434 Personnel related costs 124,669 106,889 246,385 213,216 Facilities, overhead and other 18,125 13,552 35,132 41,702 Research and development costs $ 629,379 $ 515,629 $ 1,124,358 $ 1,038,352 11 Foreign Currency Transaction Gain or Loss The Company and its foreign subsidiary use the U.S. dollar as its functional currency and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are carried at historical rates. Fair Value Measurements The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability. The Company’s financial instruments included cash, cash equivalents, restricted cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations, deposits, and the Company’s 8% Senior Secured Convertible Promissory Notes (the “Convertible Notes”), due March 2027. The carrying amount of these financial instruments, except for investment in debt securities and Convertible Notes, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes. See Note 4 for additional information related to the Convertible Notes. Income Taxes For the six months ended June 30, 2025, there was no provision for income taxes or unrecognized tax benefits recorded. As of June 30, 2025 and December 31, 2024, deferred tax assets were $ 18.8 million and $ 17.6 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100 % valuation allowance against deferred tax assets as of June 30, 2025 and December 31, 2024. Stock-Based Compensation We recognize all share-based payments to employees, consultants, and our Board of Directors (the “Board”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options, were exercised and converted into common stock, calculated by applying the treasury stock method. For the three and six months ended June 30, 2025, a total of 6,064,253 shares of potentially dilutive securities, including 64,656 shares of unvested restricted stock units and options to purchase 5,999,597 shares of common stock, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive. For the three and six months ended June 30, 2024, a total of 5,948,147 shares of potentially dilutive securities, including 117,925 shares of unvested restricted stock units and options to purchase 5,830,22 shares of common stock, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive. New Accounting Pronouncements as of June 30, 2025 In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic ASC 740) Income Taxes. The ASU improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 will become effective for our annual disclosures for the fiscal year ending December 31, 2025. We do not expect that this guidance will have a material impact on our financial position and our results of operations. In November 2024, the FASB issued ASU 2024-03 – Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). The guidance enhances the disclosures about an entity’s expenses by requiring more detailed information about the types of expenses in commonly presented expense captions. This guidance is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. We are currently evaluating the impact of adopting this guidance. On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act (“OBBBA”) of 2025 which includes, among other provisions, changes to the U.S. corporate income tax system, including the allowance of 100% expensing of qualified asset expenditures, immediate expensing of qualifying domestic research and development expenses and permanent extensions of certain other provisions within the Tax Cuts and Jobs Act. Certain provisions are effective for 2025, beginning January 19, 2025. We are evaluating the impact of these tax law changes on our consolidated financial statements. Other recent authoritative guidance issued by the FASB (including technical corrections to the Accounting Standards Codification (“ASC”)) and the SEC did not or are not expected to have a material effect on our consolidated financial statements. 12 Note 2: Cash, Cash Equivalents, and Investments The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, net of allowance for credit losses, and its investments in money market funds are classified as available-for-sale securities and presented as cash equivalents or restricted cash equivalents on the consolidated balance sheets. The following table shows the Company’s cash, available-for-sale securities, and investment securities by major security type as of June 30, 2025, and December 31, 2024: Schedule of Cash and Cash Equivalents and Investments June 30, 2025 (Unaudited) Level (1) Fair Value Allowance for Credit Losses Gross Unrealized Holding Gains Gross Unrealized Holding Losses Adjusted Cost Assets: Cash deposit 1 $ 1,878,460 $ — $ — $ — $ 1,878,460 Money market funds (2) 1 2,095,970 — — — 2,095,970 Short-term investment in corporate bonds (3)(5)(6) 2 2,841,103 — — ( 1,316 ) 2,842,419 Long-term investment in corporate bonds (4)(5)(6) 2 410,323 653 — 409,670 Total financial assets $ 6,815,533 $ — $ — $ ( 1,316 ) $ 7,226,519 Reconciliation to cash, cash equivalents and investments on the condensed consolidated balance sheet Minus: Restricted cash and cash equivalents, current and noncurrent ( 1,833,531 ) Total cash, cash, cash equivalents and investments $ 5,392,988 December 31, 2024 (Audited) Level (1) Fair Value Allowance for Credit Losses Gross Unrealized Holding Gains Gross Unrealized Holding Losses Adjusted Cost Assets: Cash deposit 1 $ 926,287 $ — $ — $ — $ 926,287 Money market funds (2) 1 5,580,463 — — — 5,580,463 Short-term investment in corporate bonds (3)(5)(6) 2 2,756,428 — — ( 149 ) 2,756,577 Total financial assets $ 9,263,178 $ — $ — $ ( 149 ) $ 9,263,327 Notes: (1) Definition of the three-level fair value hierarchy: ● Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities ● Level 2 - Other inputs that are directly or indirectly observable in the markets ● Level 3 - Inputs that are generally unobservable (2) All our money market funds were invested in U.S. Government money market funds. (3) Short-term investment securities will mature within 12 months or less, from the applicable reporting date. (4) Long-term investment securities will mature between 12 months and 18 months from the applicable reporting date. (5) For the three months ended June 30, 2025 and 2024, the Company received discounts of $ 9,618 and $ 31,357 to purchase held-to-maturity investment securities, respectively. For the six months ended June 30, 2025 and 2024 , the Company received discounts of $ 15,722 and $ 61,472 to purchase held-to-maturity investment securities, respectively. For the year ended December 31, 2024, the Company received discounts of $ 78,770 to purchase held-to-maturity investment securities. (6) The Company considers the decline in the market value of its investment portfolio to be temporary in nature. As of June 30, 2025 and December 31, 2024, the Company did not consider any of its investments to be other-than-temporarily impaired and no allowance for credit losses was recorded. Note 3: Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies Gates Foundation Grant In November 2024, the Gates Foundation (the “Gates Foundation”, formerly known as the Bill & Melinda Gates Foundation) awarded the Company a grant in the amount of $ 3,092,136 for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company’s C1 platform to provide globally accessible treatment options for underserved populations (the “Gates Foundation Grant”). As of June 30, 2025, the Company has received approximately $ 2.3 million of the Gates Foundation Grant. The remaining award of approximately $ 0.7 million is expected to be received later in 2026, subject to potential modifications of timing and amounts. The Company is required to apply the funds it receives under the agreements solely toward direct costs for the applicable funded projects, other than less than 15% of such funds, which it may apply toward general overhead and administrative expenses that support the entire operations of the Company. The Company receives funding in advance and tracks and reports eligible expenses incurred to the Gates Foundation. Funds received in advance that have not been spent are recorded as restricted cash and cash equivalents and as deferred research and development obligations in the Company’s consolidated balance sheets. As the Company incurs costs associated with research and development related to the project, on a monthly basis, the Company reclasses amounts from the grant to recognize grant revenue and cost of grant revenue. The deferred research and development obligations also include grant funds spent but not yet expensed in accordance with GAAP. The grant agreements include the Gates Foundation’s discretionary termination provisions. Any grant funds that have not been used or committed to the funded project must be returned promptly to the Gates Foundation upon expiration or termination of the agreement. For the three and six months ended June 30, 2025, the Company recognized grant revenue of $ 361,759 and $ 538,107 , respectively, in connection with the Gates Foundation Grant. For the three and six months ended June 30, 2025, the Company recognized cost of grant revenue of $ 349,558 and $ 492,849 , respectively, in connection with the Gates Foundation Grant. As of June 30, 2025, the Company had restricted cash and cash equivalents, current of $ 1,588,384 , restricted cash and cash equivalents, noncurrent of $ 245,147 , and deferred research and development obligations of $ 1,833,531 related to the Gates Foundation Grant. Coalition for Epidemic Preparedness Innovations (CEPI) Grant On March 20, 2025, the Company received a funding award from CEPI to advance Dyadic’s C1 platform through a $ 4.5 million grant through Fondazione Biotecnopolo di Siena (“FBS”) to accelerate recombinant protein vaccine development and manufacturing. The funding will support antigen design, cell line development, optimization, characterization, and scale-up to cGMP manufacturing. If successful, the next phase will focus on selecting a CEPI-priority pathogen antigen. Dyadic, as a subcontractor, will receive up to $ 2.4 million of the total grant funding. The Company will be reimbursed for research and development expenses in arrears on a quarterly basis. For the three and six months ended June 30, 2025, the Company recognized grant revenue of $ 141,422 and $ 175,545 , respectively, in connection with the CEPI Grant. For the six months ended June 30, 2025, the Company recognized cost of grant revenue of $ 115,576 and $ 143,463 , respectively, in connection with the CEPI Grant. 13 Proliant On June 27, 2024 , the Company entered into a License and Development Agreement (the “Proliant Agreement”) with Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals (“Proliant”), pursuant to which, Proliant will license Dyadic’s proprietary fungal microbial expression and production platforms and microbial strains for the production of recombinant serum albumin, for an initial period of 10 years with an option to extend for an additional 3 years under certain circumstances. Under the terms of the Proliant Agreement, Dyadic has received an initial upfront payment of $ 500,000 and a second payment of $ 500,000 upon the completion of the transfer of a Production Strain (as defined in the Proliant Agreement.) for the year ended December 31, 2024. The Company expects to receive a final payment of $ 500,000 in the third quarter of 2025 upon meeting a certain productivity threshold. For the three and six months ended June 30, 2025, the Company did not receive any additional payments under the Proliant Agreement. Upon commencing commercial sales of animal-free recombinant serum albumin products produced pursuant to the Proliant Agreement, the Company will receive royalties based on a certain percentage of the gross margin received by Proliant, as defined in the Proliant Agreement. Inzymes ApS On September 18, 2023, Dyadic International (USA) Inc., a subsidiary of the Company, signed a Development and Exclusive License Agreement (the “Inzymes Agreement”) with Inzymes ApS (“Inzymes”), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic’s proprietary Dapibus™ platform. In October 2023, the Company received an upfront payment of $ 0.6 million in accordance with the terms of the Inzymes Agreement. On October 11, 2024, the Inzymes Agreement was amended (“the Amended Inzymes Agreement”) to change the scope of research and development services required under the agreement as well as adjust the success fees upon the achievement of certain target yields, milestone payments upon first commercial sale of each product and royalties. For the year ended December 31, 2024, the Company has completed all product research and development services and satisfied all related performance obligations under the Amended Inzymes Agreement, and recognized $ 890,169 in license revenues, including success fees upon the achievement of target yield of one related product. For the year ended December 31, 2024, the Company also recognized research and development revenues of $ 25,000 related to the Amended Inzymes Agreement. For the three and six months ended June 30, 2025, the Company recognized milestone revenue of $ 250,000 upon the achievement of commercially viable target yield related to the Inzymes Agreement. The Company will continue evaluating the achievement of milestones related to target yields and product commercialization of each product when they are considered probable and estimable under the Inzymes Agreement. Alphazyme In 2019 the Company entered into a sub-licensing agreement with Alphazyme, LLC (“Alphazyme”) that was subsequently amended (the “Amended Alphazyme LLC Agreement”). Under the Amended Alphazyme LLC Agreement, Alphazyme obtained additional capital contribution and Dyadic’s ownership was diluted to 1.99 %. The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investment in Alphazyme. The Company reports its investment in Alphazyme under the cost method of accounting, given that it does not have the ability to exercise significant influence or control over Alphazyme. On January 18, 2023, the Company entered into a Securities Purchase Agreement, under which the Company agreed to sell its equity interest in Alphazyme, LLC (the “Alphazyme Sale Agreement”). The Company continues to have the potential to receive additional payments based on the future sales of Alphazyme’s existing products, pursuant to the Alphazyme Sale Agreement. The Amended Sublicense Agreement between Dyadic and Alphazyme, which was previously entered on June 24, 2020, remains in effect. Under the Amended Alphazyme Sub-License Agreement, Dyadic is entitled to potential milestone and royalty payments upon the commercialization of Alphazyme products using Dyadic’s proprietary C1-cell protein production platform. For the year ended December 31, 2024, the Company received a total cash payment of $ 1.3 million from the sale of its equity interest in Alphazyme, LLC. In the first quarter of 2024, the Company received an additional cash payment of $ 60,977 , which was recorded as gain on sale of Alphazyme in the consolidated statement of operations. There was no revenue recognized related to Alphazyme in 2025. Note 4: Convertible Notes Payable On March 8, 2024, the Company issued senior secured convertible promissory notes (the “Convertible Notes”) with an aggregate principal amount of $ 6.0 million, of which, $ 2.0 million were sold to related parties, including immediate family members and family trusts related to Mark Emalfarb, our Chief Executive Officer and a member of our Board of Directors. The Convertible Notes are senior, secured obligations of the Company and its affiliates, and interest is payable quarterly in cash on the principal amount equal to 8 % per annum, and guaranteed by its subsidiary, Dyadic International (USA), Inc. under a subsidiary guarantee for the benefit of the holders of the Convertible Notes (each such holder, a “Holder”). The Convertible Notes mature on March 8, 2027, unless earlier converted or redeemed in accordance with the terms of the Convertible Notes. The Convertible Notes are secured by a first priority lien on substantially all assets of the Company and Dyadic International (USA), Inc. The Convertible Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options and ASC 815-15, Derivatives and Hedging . Under ASC 815, contracts that are both indexed to its own stock and classified in stockholders’ equity in its statement of financial position are not considered to be derivative instruments. Based on the Company’s analysis, it is determined that the Convertible Notes contain embedded features that are indexed to the Company’s own stock and are classified in stockholders’ equity in the Company’s statement of financial position, but do not meet the requirements for bifurcation and recognition as derivatives, and therefore, do not need to be accounted for separately. Accordingly, the proceeds received from the issuance of the Convertible Notes were recorded as a single liability in accordance with ASC 470 on the Company’s consolidated balance sheets. 14 The Company incurred $ 175,674 of debt issuance costs associated with the Convertible Notes, which were recorded as a reduction of the Convertible Notes on the consolidated balance sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the Convertible Notes using the effective interest method. We determined that the expected life of the debt is equal to the three 5 -year term of the Convertible Notes. On October 4, 2024, the Company entered into an amendment (the “Amendment”) to the Convertible Notes. Under the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company’s common stock is $ 1.40 per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fall on any of the 26, 29 and 32-month anniversaries of the original issue date of the Convertible Notes. On May 1, 2025, the Company entered into a second amendment (the “Second Amendment”) to the Convertible Notes. Pursuant to the Second Amendment, the Redemption Date (as defined in the Second Amendment) will now fall on December 1, 2026. The Company assessed the Amendment and Second Amendment for a debt extinguishment or modification in accordance with ASC 470-50. As both the change in the present value of future cash flows of the modified Convertible Notes to that of the original Convertible Notes (including callable features) and the change in fair value of the embedded conversion option to that of the carrying value of the Convertible Notes immediately before modification resulted in a less than 10% change, neither Amendments was deemed substantial and they are regarded as a note modifications. The Company did not incur any gain or loss relating to the modifications and any incremental costs related to the Amendments were expensed. For the three and six months ended June 30, 2025, $ 101,800 and $ 208,973 of interest were paid, and debt issuance costs of $ 12,032 and $ 23,795 were amortized and recorded in interest expenses in the consolidated statements of operations, respectively. For the three and six months ended June 30, 2024, $ 34,844 and $34,844 of interest were paid, and debt issuance costs of $ 23,591 and $26,716 were amortized and recorded in interest expenses in the consolidated statements of operations, respectively. As of June 30, 2025, the accrued interest on the Convertible Notes to related parties and other third parties was $ 21,800 and $ 80,000 , respectively. As of June 30, 2024, the accrued interest on the Convertible Notes to related parties and other third parties was $ 32,000 and $ 80,000 , respectively. As of June 30, 2025 and 2024, accumulated amortized debt issuance costs are $ 60,171 and $ 26,716 , respectively. During the year ended December 31, 2024, $ 910,000 of the Convertible Notes were converted into 556,623 shares of the Company’s common stock. As of June 30, 2025, convertible notes payable consisted of the following: Schedule of Convertible Notes Payable Holder Issuance Date Due Date Interest Rate Convertible Note Principal Principal Repayments Conversion to Common Stock Principal Outstanding Francisco Trust dated 2/28/1996 (1) 03/08/24 03/08/27 8 % $ 1,000,000 $ — $ — $ 1,000,000 Bradley Emalfarb (2) 03/08/24 03/08/27 8 % 500,000 — ( 500,000 ) - Bradley Scott Emalfarb Irrevocable Trust (2) 03/08/24 03/08/27 8 % 410,000 — ( 410,000 ) - Emalfarb Descendent Trust (3) 03/08/24 03/08/27 8 % 90,000 — — 90,000 Convertible Notes - Related Party $ 2,000,000 $ — $ ( 910,000 ) 1,090,000 Unamortized Debt Issuance Costs - Related Party ( 19,029 ) Net Carrying Amount $ 1,070,971 Convertible Notes - Third Party 03/08/24 03/08/27 8 % $ 4,000,000 $ — $ — 4,000,000 Unamortized Debt Issuance Costs - Third Party ( 69,830 ) Net Carrying Amount $ 3,930,170 Notes: (1) Mr. Thomas Emalfarb, nephew of Mr. Mark A. Emalfarb, our Chief Executive Officer, is the Trustee of the Francisco Trust. Mr. Thomas Emalfarb may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. The amount of accrued interest as of June 30, 2025, is $ 20,000 . (2) Mark A. Emalfarb, our Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr. Bradley S. Emalfarb, who is the sole beneficiary of the Irrevocable Trust. Mr. Bradley S. Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore, may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly. In 2024, $500,000 of the Convertible Notes held by Mr. Bradley S. Emalfarb were converted into 294,891 shares of the Company’s common stock and $410,000 of the Convertible Notes held by Bradley Scott Emalfarb Irrevocable Trust were converted into 261,732 shares of the Company’s common stock. As of June 30, 2025, there is no accrued interest for Bradley Emalfarb and Bradley Scott Emalfarb Irrevocable Trust. (3) Messrs. Thomas Emalfarb, Scott Emalfarb and Michael Emalfarb, nephews of Mr. Mark A. Emalfarb, our Chief Executive Officer, are co-trustees of the Descendant Trust and may therefore be deemed to have shared voting, dispositive and investment power over the shares of common stock held by the Descendant Trust. The amount of accrued interest as of June 30, 2025, is $1,800. 15 Note 5: Commitments and Contingencies Legal Proceedings We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations. VTT Research Contract On July 1, 2025, the Company entered into a Fifth Amendment to the commission contract concerning VTT Technical Research Centre of Finland Ltd. (“VTT”) to continue developing Dyadic’s C1 fungal expression system (the “Fifth Amendment”). The original contract was entered on June 28, 2019, and subsequently amended by the First Amendment on June 21, 2022, the Second Amendment on September 9, 2022, the Third Amendment on January 31, 2024, and the Fourth Amendment on February 19, 2025. Under the terms of the Fifth Amendment, the contract duration was extended to September 30, 2025, and Dyadic will pay VTT a total of approximately EUR104,000. Note 6: Share-Based Compensation Description of Equity Plans The 2021 Equity Incentive Award Plan (the “2021 Plan”) was adopted by the Company’s Board of Directors on April 9, 2021 and approved by the Company’s Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2021. The 2021 Plan serves as a successor to the Company’s 2011 Equity Incentive Plan (the “2011 Plan”). Since the adoption of the 2021 Plan, all equity awards were made from the 2021 Plan and no additional awards will be granted under the 2011 Plan. The 2021 Plan provides for the issuance of a variety of share-based compensation awards, including stock options, restricted stock awards, restricted stock unit awards, performance awards, dividend equivalents awards, deferred stock awards, stock payment awards and stock appreciation rights. As of April 16, 2021, the 2021 Plan increased the number of shares available for grant by 3,000,000 in addition to the number of shares remaining available for the grant of new awards under the 2011 Plan. As of June 30, 2025, the Company had 5,999,597 stock options outstanding and 64,656 unvested restricted stock units in addition to 1,571,382 shares of common stock available for grant under the 2021 Plan. As of December 31, 2024, the Company had 5,788,597 stock options outstanding and 117,925 unvested restricted stock units in addition to 2,056,629 shares of common stock available for grant under the 2021 Plan. Stock Options Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan and 2021 Plan is ten years , except for certain options granted to the contractors, which are two 2 to five years . The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following. Risk-free interest rate . The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant. Expected dividend yield . The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatilities since 2016. 16 Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option. The assumptions used in the Black-Scholes option pricing model for stock options granted for the six months ended June 30, 2025, are as follows: Schedule of Stock Options Risk-Free interest rate 4.1 % - 4.4 % Expected dividend yield — % Expected stock price volatility 65.1 - 65.4 % Expected life of options (in years) 0.8 - 6.3 The following table summarizes the stock option activities for the six months ended June 30, 2025: Schedule of Stock Option Activities Weighted-Average Weighted-Average Remaining Contractual Aggregate Intrinsic Shares Exercise Price Term (Years) Value Outstanding at December 31, 2024 5,788,597 $ 2.97 5.34 $ 655,578 Granted (1) 698,500 1.71 Exercised (2) ( 55,000 ) 1.17 Canceled (3) ( 432,500 ) 3.13 Outstanding at June 30, 2025 5,999,597 $ 2.83 5.60 $ — Exercisable at June 30, 2025 4,768,372 $ 3.09 4.77 $ — Notes: (1) Represents the following options granted: ● Annual share-based compensation awards on January 2, 2025, with an exercise price of $ 1.74 , including: (a) 356,500 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years , (b) 277,500 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 19,500 stock options granted to employees, vesting annually in equal installments over four years , and (d) 20,000 stock options granted to a consultant, vesting upon one year anniversary. ● One time share-based compensation award on May 30, 2025, with an exercise price of $ 1.04 , of 25,000 stock options granted to an executive, vesting annually in equal installments over four years. (2) Represents the following options exercised: (a) 25,000 stock options with an exercise price of $ 0.97 per share exercised by a board member (b) 30,000 stock options with an exercise price of $ 1.33 per share exercised by a board member. (3) Represents the following options canceled: (a) 55,000 stock options with an exercise price of $ 1.75 per share granted to a consultant, (b) 75,000 stock options with an exercise price of $ 4.10 per share granted to key personnel, (c) 37,500 stock options with an exercise price of $2.23 per share granted to a consultant, and (d) 265,000 stock options with a weighted average exercise price of $3.28 per share granted to a former board member. Restricted Stock Units Restricted stock units (the “RSUs”) are granted subject to certain restrictions. Vesting conditions are determined at the discretion of the Board of Directors. The fair market value of RSUs is generally determined based on the closing market price of the stock on the grant date. The following table summarizes the restricted stock award activity for the six months ended June 30, 2025: Schedule of Restricted Stock Award Activity Weighted-Average Grant Date Shares Fair Value Outstanding at December 31, 2024 117,925 $ 1.59 Granted (1) 230,023 1.74 Vested (2) ( 272,516 ) 1.67 Forfeited (3) ( 10,776 ) 1.74 Outstanding at June 30, 2025 64,656 $ 1.74 Notes: (1) On January 2, 2025, the Company granted 96,984 restricted stock units, vesting upon one year anniversary, to the Board of Directors as a result of reduction in director cash compensation of 2025, and an aggregate of 133,039 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended December 31, 2024. (2) Represents the vesting 133,039 RSUs granted to executives and key personnel, and 139,477 RSUs granted to the Board of Directors. (3) Represents the cancellation of unvested RSUs granted to a former member of the Board of Directors. 17 Compensation Expenses We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. For the three and six months ended June 30, 2025, there were forfeitures of $ 0 and $ 16,880 , respectively. For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date. Total non-cash share-based compensation expense was allocated among the following expense categories: Schedule of Non-cash Share-based Compensation Expense Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 General and administrative $ 323,321 $ 285,372 $ 531,317 $ 579,406 Research and development 17,141 12,231 34,175 24,675 Total $ 340,462 $ 297,603 $ 565,492 $ 604,081 The following table summarizes the Company’s non-cash share-based compensation expense allocation between options and restricted stock units: Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Share based compensation expense - stock option $ 304,861 $ 243,538 $ 482,155 $ 433,807 Share based compensation expense - restricted stock units 35,601 54,065 83,337 170,274 Total $ 340,462 $ 297,603 $ 565,492 $ 604,081 Note 7: Shareholders’ Equity Issuances of Common Stock For the six months ended June 30, 2025, there were 272,516 shares issued from the vesting of restricted stock units with a weighted average issue price of $ 1.68 per share and 55,000 shares issued from the exercise of stock options. For the six months ended June 30, 2024, there were 666,578 shares of the Company’s common stock issued with a weighted average issue price of $ 1.61 per share, including 223,463 shares from the conversion of the Convertible Notes, 61,793 shares from the vesting of restricted stock units, and 5,569 shares from the exercise of stock options. Treasury Stock As of June 30, 2025, there were 12,253,502 shares of common stock held in treasury, at a cost of $ 18.9 million, representing the purchase price on the date the shares were surrendered to the Company. 18 Note 8: Segment The Company operates and manages its business as one reportable segment and one operating segment, which is the business of developing and commercializing synthetic protein products using the Company’s proprietary microbial platforms, including C1 and Dapibus TM . The Company’s chief operating decision maker, or CODM, is the Company’s senior management team that includes the Chief Executive Officer, President & Chief Operating Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The Company operates in the U.S. and Europe. All material long-lived assets of the Company reside in the U.S. For geographic information about the Company’s product revenues, see Note 1, Concentration . Long-lived assets primarily consist of operating lease right-of-use assets. The CODM uses consolidated net loss to evaluate the Company’s spending and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing the performance of segment and in establishing resource allocation across the organization. Factors used in determining the reportable segment include the nature of the Company’s operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 1 of the notes to the consolidated financial statements included in this Annual Report on Form 10-K. The CODM reviews cash, cash equivalents and investment securities as a measure of segment assets. As of June 30, 2025 and December 31, 2024, the Company’s cash, cash equivalents and investment securities were $ 7.3 million and $ 9.3 million, respectively. The following table presents information about segment revenue, significant segment expenses and segment operating loss for the three and six months ended June 30, 2025 and 2024: Schedule of Segment Revenue, Significant Segment Expenses and Segment Operating Loss Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Total revenues $ 966,630 $ 385,896 $ 1,360,202 $ 720,513 Total cost of revenues 613,591 301,956 911,249 445,911 Research and development expenses: Outside contracted services 486,585 395,188 842,841 783,434 Personnel related costs 107,528 94,658 212,210 188,541 Facilities, overhead, and other 18,125 13,552 35,132 41,702 General and administrative expenses: — — — — Compensation and related expenses 581,276 583,423 1,213,798 1,249,903 Business consulting expenses 71,100 210,980 252,327 417,352 Legal and professional services 209,579 224,906 540,676 590,065 Other G&A expenses 251,379 303,076 494,850 559,874 Share-based compensation expenses 340,462 297,602 565,492 604,081 Foreign currency exchange loss 16,098 3,146 23,170 8,049 Other Income (expenses), net 64,706 2,632 89,810 ( 113,330 ) Net loss $ 1,793,774 $ 2,045,223 $ 3,821,353 $ 4,055,069 Note 9: Subsequent Event For the purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through August 13, 2025, the date the consolidated financial statements were available to be issued. Except for items mentioned in the notes, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements. On July 30, 2025, the Company entered into an Underwriting Agreement, which closed on August 1, 2025 for net proceeds of $ 5.3 million. See Note 1 for additional details. 19 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but are not limited to, those set forth in “ Item 1A. Risk Factors ” in this Quarterly Report. All forward-looking statements included in this Quarterly Report are based on information available to us as of the time we file this Quarterly Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements. Overview Description of Business Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company headquartered in Jupiter, Florida, with operations in the U.S. and the Netherlands. We aim to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. Our proprietary platforms—Dapibus™ and C1—are designed for rapid, cost-effective, and flexible production of high-value proteins, enabling partners to reduce development timelines and manufacturing costs. While Dyadic’s primary focus is on non-therapeutic applications, both platforms retain the capability to produce biologics, such as vaccines and therapeutic proteins, for external partners. Platform Capabilities Dyadic’s Dapibus™ and C1 platforms are engineered microbial expression systems optimized for high-yield, low-cost, and scalable protein production. Built on decades of industrial experience, these platforms support applications in: ● Cell culture media (e.g., albumin, transferrin, fibroblast growth factor (“FGF”)) ● Diagnostics and research reagents ● Functional food ingredients (e.g., alpha-lactalbumin, caseins, lactoferrin) ● Sustainable industrial enzymes (e.g., biomass and dairy enzymes) By targeting high-value proteins in expanding non-pharmaceutical markets, Dyadic is building a commercial pipeline that aligns with global trends in sustainability, animal-free manufacturing, and bio-based innovation. Simultaneously, we continue to explore partnering opportunities for the use of our platforms in pharmaceutical development where appropriate. Dapibus™ Protein Production Platform To accelerate commercialization and reduce regulatory risk, Dyadic developed the Dapibus™ platform—a proprietary expression system designed to produce high-value, non-animal proteins and enzymes for non-pharmaceutical markets including life sciences, food and nutrition, and bio-industrial sectors. Dapibus™ is expected to enable faster development, lower production costs, and simplified regulatory pathways compared to therapeutic biologics, which Dyadic believes will allow it to address growing demand for sustainable, functional ingredients across a range of industries. The platform supports applications in bioprocessing, product formulation, diagnostics, and nutrition. Dyadic expects to commercialize multiple Dapibus™-enabled products starting in 2025 through a combination of strategic partnerships and internal manufacturing initiatives. 20 C1 Protein Production Platform Dyadic’s proprietary C1 expression system is a patented, thermophilic fungal platform ( Thermothelomyces heterothallica fungus) developed for the cost-effective, large-scale production of proteins. Originally used to manufacture industrial enzymes, Dyadic has engineered C1 into a high-yield, scalable platform for both biopharmaceutical and non-pharmaceutical applications. Following the 2015 sale of its industrial enzyme business to Danisco USA (a DuPont subsidiary), Dyadic retained co-exclusive rights to the C1 platform for human and animal pharmaceutical use, including the exclusive ability to sub-license C1 for human and animal pharmaceutical use (subject to specific conditions). Danisco holds certain retained rights but is obligated to pay Dyadic royalties on any future pharmaceutical commercialization. Dyadic may owe downstream royalties to Danisco or its licensors depending on specific patent usage. Food and Nutrition Applications Dyadic is applying Dapibus™ to develop and commercialize animal-free proteins for dairy alternatives and functional nutrition. Key programs include: ● Dairy Enzyme Program: Under a development and exclusive license agreement signed in 2023, Dyadic received a $600,000 upfront payment and an additional $425,000 milestone payment in September 2024 for achieving target yield. Commercial launch by the partner is expected in late 2025. ● Recombinant Bovine Alpha-Lactalbumin: An improved production strain was developed in 2024. The product shows comparability to commercial benchmarks and is being actively sampled and characterized for use in dairy alternatives. ● Recombinant Human Alpha-Lactalbumin: Development was initiated in 2024 for applications in infant formula, medical nutrition, nutraceuticals, and pharmaceuticals. ● Recombinant Human Lactoferrin: A cell line was developed in 2024 for potential use in immune-supportive and antimicrobial products. Sampling is expected to begin in Q3 2025. ● Casein Proteins: Four casein variants have been produced, and Dyadic is engaged in discussions with prospective commercial partners. 21 Life Sciences Our C1 platform is a robust and versatile gene expression system designed for the efficient production of high-value input proteins that power the life sciences sector, such as cell culture media components, molecular biology reagents, and other critical bioprocessing inputs. Cell Culture Media Dyadic seeks to leverage its microbial platforms to produce high-value, animal-free growth media components for the biopharma and alternative protein markets. Key developments include: ● Recombinant Serum Albumin: In partnership with Proliant Health and Biologicals, Dyadic is advancing toward a 2025 commercial launch of animal-free serum albumin for cell culture, diagnostics, and vaccine stabilization. Dyadic has received $1.0 million in milestone payments to date, with additional payments and royalties tied to commercial success. Early data show strong comparability to industry standards and efficacy in cultured meat applications. Additionally, the Company anticipates achieving a third milestone payment of $500,000 in Q3 2025 related to productivity improvements and future revenue sharing payments for commercial sales. ● Recombinant Transferrin: Dyadic’s animal-free transferrin demonstrated equivalent performance to leading recombinant standards. Samples are being evaluated for research, diagnostics, and commercial bioprocessing. ● Recombinant Fibroblast Growth Factor (FGF): Critical for cell proliferation, Dyadic’s bovine FGF candidate has shown promising results in early testing for biopharma and cultivated meat applications. Efforts are underway to improve productivity, with additional characterization and validation ongoing. Sampling to cell culture, diagnostic and research markets is underway. ● Strategic Co-Promotion: Dyadic has partnered with Biftek Co. to jointly promote growth media supplements for cell culture markets. DNA/RNA Technologies Dyadic is expanding into molecular tools for diagnostics and life sciences, with several enzyme products in development: ● DNase-1 (RNase-free): We completed development; production validation ongoing with a European Contract Development and Manufacturing Organization (“CDMO”). A research-grade product is expected by the end of 2025. Sampling is active, with ongoing discussions for potential partnerships and agreements across multiple markets ● RNA/DNA Toolkit: Development is underway for RNase Inhibitors, T7 RNA Polymerase, DNA Ligase, and Polymerases. Prototype enzymes have been produced, with optimization continuing into late 2025 and into 2026. Bio-Industrial Applications Dyadic seeks to leverage its Dapibus™ platform to develop and commercialize cost-effective, scalable enzyme solutions for bio-industrial markets, supporting the global shift toward a more sustainable bioeconomy. ● Strategic Partnership with Fermbox Bio: In 2023, Dyadic partnered with Fermbox Bio to develop EN3ZYME, a proprietary enzyme cocktail launched in May 2024 for converting agri-residues into fermentable cellulosic sugars. Fermbox received an initial large purchase order in Q1 2025 with initial enzyme delivery completed in Q2 2025. Dyadic is expected to receive a 50/50 revenue profit share from commercial sales. ● Sustainable Enzyme Portfolio: Dyadic is advancing enzymes applicable to multiple sectors, including nutrition, pulp and paper, biogas, and biofuels. Sampling to potential commercial partners is ongoing. ● Hyaluronidase Development: Initiated in 2024, this enzyme targets high-value markets including medical, cosmetic, and reproductive health. Sampling and commercial engagement are underway. Pharmaceutical Applications While Dyadic is focused on non-therapeutic markets, the C1 platform remains a validated solution for biopharmaceutical manufacturing and continues to attract interest from pharma, CDMOs, academic institutions, and government agencies. C1 addresses key bottlenecks in biologics manufacturing—reducing cost, shortening development cycles, and enabling higher yields—positioning it as a competitive alternative to CHO, yeast, and insect cell systems. Strategic opportunities include: ● Recombinant vaccines and therapeutics (human and animal) ● Biobetters and biosimilars ● Drug formulation and diagnostic reagents ● Cost-effective production of difficult-to-express proteins Dyadic continues to evaluate licensing, collaboration, and commercialization opportunities to unlock C1’s full potential in the biologics sector. 22 Legacy Biopharma Programs Support Strategic Growth and Platform Validation Dyadic’s legacy pharmaceutical initiatives continue to drive platform validation, unlock non-dilutive funding, and support strategic collaborations without diverting focus from its core commercial goals. Fully Funded Global Health Collaborations ● Gates Foundation: We were awarded a grant in November 2024 to develop C1-based mAbs targeting RSV and malaria for underserved populations. ● Israel Institute for Biological Research: We are in an ongoing collaboration to co-develop vaccines and biologics for emerging diseases and biothreats. ● Fondazione Biotecnopolo di Siena / CEPI: Beginning March 2025, we are part of a $4.5 million CEPI-funded project, eligible for $2.4 million, to accelerate development of C1-produced recombinant vaccines for global pandemic preparedness. ● Dyadic participated in the inaugural European Vaccines Hub for Pandemic Readiness (“EVH”) meeting, May 22–23, 2025. Led by Dr. Rino Rappuoli, Scientific Director of Fondazione Biotecnopolo di Siena, the EVH aims to establish a centralized EU hub for vaccine innovation, integrating R&D, clinical trials, and scalable manufacturing. Backed by approximately €100 million in EU funding over four years, the initiative brings together leading public and private developers. Dyadic’s C1 microbial expression technology is expected to be among the platform technologies evaluated, highlighting its potential to accelerate development and reducing the cost of manufacturing vaccines and antibodies at scale. ● On March 23, 2025, CEPI announced a grant of $2.6 million to Uvax Bio. A portion of this funding will support the development of a MERS vaccine and research to assess the capability of the C1 platform to speed vaccine production and lower manufacturing costs. Advancing C1 Vaccine Capabilities ● Ferritin Nanoparticle Vaccine Candidates (with ViroVax): ○ H5 Avian Influenza: Demonstrated cross-protection in early trials; commercial interest in poultry, cattle, and human markets. ○ Mpox: Early-stage preclinical development reinforcing C1’s rapid response and low-cost manufacturing potential. Diagnostics and Animal Health Expansion ● C1-produced H5 antigens show strong neutralizing antibody response in poultry and promising cross-protection in cattle — with the potential to open new opportunities in animal health and diagnostics. Strategic Platform Partnerships ● Cygnus Technologies® (Maravai LifeSciences®): C1 Host Cell Protein (HCP) ELISA Kit to support C1/Dapibus™ regulatory workflows commercially launched. ● Rabian BV: We are awaiting funding from the Eurostars program for a rabies vaccine project using the C1 platform; Dyadic is expected to receive equity in Rabian BV, certain milestone payments, and royalties on commercial sales. 23 Peer-Reviewed Validation and Clinical Progress ● Nature Communications: C1-produced mAb showed protection against Omicron and Delta variants in non-human primates. ● DYAI-100 Vaccine Candidate: Phase 1 clinical trial met safety and immunogenicity endpoints. Future development paused to focus on emerging variants in collaboration with Rubic One Health (“Rubic”). These legacy programs provide critical third-party validation of the C1 platform’s biopharmaceutical potential while generating non-dilutive capital and enabling future commercial opportunities. Licensing and Strategic Collaborations In April 2023, Dyadic expanded its license agreement with Rubic to include vaccines and therapeutic proteins for both human and animal health in underserved African markets. The C1 platform tech transfer is complete. Dyadic is eligible to receive milestone payments, royalties, and marketing rights under the agreement. In 2024, Rubic initiated development of several livestock vaccines. Dyadic entered an exclusive sublicense agreement with Abic, an affiliate of Phibro Animal Health Corporation, in February 2022. The agreement was expanded in March 2024 to include additional vaccines and treatments for livestock diseases. Research and Development Dyadic conducts internal and collaborative R&D to advance its microbial platforms across both pharmaceutical and non-pharmaceutical applications. VTT Technical Research Centre of Finland Since 2016, Dyadic has partnered with VTT, a leading European research institute, to enhance C1’s safety, productivity, and efficiency. VTT supports critical initiatives including glycoengineering, protease deletion, and therapeutic protein expression. Many projects at VTT are co-funded by Dyadic’s third-party collaborators. Other CRO and CDMO Partnerships Dyadic works with a global network of research providers and manufacturers, including 53Biologics (Spain), Fermbox Bio (India), and Eleszto Genetika (Hungary). These partners support the Company’s R&D and scale-up activities across its platforms. While typically structured as work-for-hire engagements, disruptions to these collaborations could impact timelines or development outcomes. 24 Other Recent Developments DBA Name Change Update On July 2, 2025, we announced that, effective on August 1, 2025, we are doing business as Dyadic Applied BioSolutions. This rebranding initiative marks a strategic transition from a research-driven organization to a commercially focused enterprise. The new name and visual identity better reflect the emphasis on delivering applied biotechnology solutions through our patented and proprietary C1 and Dapibus™ gene expression platforms. Nasdaq Deficiency Notices As previously disclosed, on June 23, 2025, the Company received a deficiency notice (the “MVLS Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities had not maintained the minimum Market Value of Listed Securities (“MVLS”) of $35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2). In addition and as previously disclosed, on July 17, 2025, the Company received a deficiency notice (the “Minimum Bid Price Notice”) from the Staff of Nasdaq notifying the Company that for the last 30 consecutive business days the Company’s common stock had not maintained the minimum bid price of at least $1.00 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The MVLS Notice and the Minimum Bid Price Notice have no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market, and the Company is currently subject to compliance periods during which it may regain compliance with the applicable rules. The Company intends to actively monitor the MVLS and the bid price of its common stock between now and the relevant compliance deadlines and, as appropriate, plans to evaluate available options to resolve the deficiencies and regain compliance with the requirements. For more information, see “ Item 1A. Risk Factors – We have in the past, and may in the future, be unable to comply with the listing standards of the Nasdaq Stock Market LLC (“Nasdaq”). If we fail to comply with listing standards in the future, our common stock may be delisted. Delisting could adversely affect the liquidity of our common stock, and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired.” Critical Accounting Estimates The preparation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements. 25 We define critical accounting estimates as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting estimates, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting estimates include the following: Revenue Recognition The Company has no products approved for sale. All our revenue to date has been research revenue from third-party collaborations and grants, as well as revenue from sublicensing agreements and collaborative arrangements, which may include upfront payments, options to obtain a license, payment for research and development services, milestone payments and royalties, in the form of cash or non-cash considerations (e.g., minority equity interest). Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best-efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Depending on how the performance obligation under our license and collaboration agreements is satisfied, we recognize the revenue either at a point in time or over time by using the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation. Under the input method, revenue will be recognized based on the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations. 26 A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified, and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. Revenue related to grants: The Company receives grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to fund the Company’s research collaborations partially or fully, including opportunities and projects that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for vaccines and/or antibodies candidates. Revenue related to grants are presented on a gross basis on the Consolidated Statements of Operations. Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer can use and benefit from the license. Customer options: If the sublicensing agreement includes customer options to purchase additional goods or services, the Company will evaluate if such options are considered material rights to be deemed as separate performance obligations at the inception of each arrangement. Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements. We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to a sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from the licensing agreement. We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed. The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less. Accrued Research and Development Expenses In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and adjust if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with research and development activities. Stock-Based Compensation We have granted stock options to employees, directors, and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., 5 or 10 years) and certain contractors (i.e., 2 to 5 years). The expected stock price volatility was calculated based on the Company’s own volatility. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatilities since 2016. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the performance-based options issued to employees, consultants, and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain. 27 Accounting for Income Taxes The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, “Income Taxes”. Under this method, income tax expense /(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized. In determining taxable income for the Company’s consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company’s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. The Company is required to evaluate the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in a company’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefits, because it represents a company’s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of ASC 740. The Company classifies accrued interest and penalties related to its tax positions as a component of income tax expense. The Company currently is not subject to U.S. federal, state, and local tax examinations by tax authorities for the years before 2021. Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements. Recent Accounting Pronouncements See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements . Results of Operations Three and Six Months Ended June 30, 2025 Compared to the Same Periods in 2024 Revenue and Cost of Revenue The following table summarizes the Company’s revenue and cost of revenue for the three and six months ended June 30, 2025 and 2024: Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Research and development revenue $ 213,449 $ 385,896 $ 396,549 $ 720,513 Grant revenue 503,181 — 713,653 — License and milestone revenue 250,000 — 250,000 — Costs of research and development revenue 148,457 301,956 274,937 445,911 Cost of grant revenue 465,134 — 636,312 — For the three months ended June 30, 2025, the decrease in research and development revenue and cost of research and development revenue was due to a reduction in the number of active collaborations to eight compared to ten for the same period a year ago. For the six months ended June 30, 2025, the decrease in research and development revenue and cost of research and development revenue was due to a reduction in the number of active collaborations to ten compared to thirteen for the same period a year ago. The grant revenue and cost of grant revenue for the three and six months ended June 30, 2025, were related to the Gates Foundation and CEPI grants. There was no grant revenue for the three and six months ended June 30, 2024. For the three and six months ended June 30, 2025, the license and milestone revenue of $250,000 was related to the Inzymes Agreement. Research and Development Expenses Research and development costs are expensed as incurred and include salary and benefits of research personnel, third-party contract research organization services and supply costs. Research and development expenses for the three months ended June 30, 2025, increased to $629,000 compared to $516,000 for the same period a year ago. The increase was driven by a rise in the number of active internal research initiatives undertaken to expedite product development. Research and development expenses for the six months ended June 30, 2025, increased to $1,124,000 compared to $1,038,000 for the same period a year ago. The increase was driven by a rise in the number of active internal research initiatives undertaken to expedite product development. 28 General and Administrative Expenses General and administrative expenses for the three months ended June 30, 2025, decreased by 10.6% to $1,437,000 compared to $1,608,000 for the same period a year ago. The decrease reflected reductions in business development and investor relations expenses of $82,000, accounting and legal expenses of $41,000, insurance expenses of $28,000, and management incentives of $22,000, partially offset by other expense increases of $2,000. General and administrative expenses for the six months ended June 30, 2025, decreased by 10.7% to $3,033,000 compared to $3,396,000 for the same period a year ago. The decrease reflected reductions in business development and investor relations expenses of $180,000, management incentives of $100,000, accounting and legal expenses of $82,000, and insurance expenses of $37,000, partially offset by other expense increases of $35,000. Loss from Operations Loss from operations for the three months ended June 30, 2025, decreased to $1,729,000 compared to $2,043,000 for the same period a year ago. The decrease in loss from operations was largely attributable to an increase in total revenue of $581,000 and a reduction in general and administrative expenses of $171,000, partially offset by increases in cost of revenue of $311,000 and research and development expenses of $113,000. Loss from operations for the six months ended June 30, 2025, decreased to $3,732,000 compared to $4,168,000 for the same period a year ago. The decrease in loss from operations was largely attributable to an increase in total revenue of $639,000 and a reduction in general and administrative expenses of $363,000, partially offset by increases in cost of revenue of $465,000 and research and development expenses of $86,000. Other Income (Expenses), Net For the three months ended June 30, 2025, total other income (expenses), net, was an expense of $65,000 compared to an income of $3,000 for the same period a year ago. The decrease in other income was largely due to a reduction of $89,000 in interest income, partially offset by a decrease in interest expenses of $28,000 related to the Convertible Notes. For the six months ended June 30, 2025, total other income (expenses), net, was an expense of $90,000 compared to an income of $113,000 for the same period a year ago. The decrease in other income was largely due to gain on sale of Alphazyme of $61,000 in 2024, decrease in interest income of $88,000 and $55,000 increase in interest expenses related to the Convertible Notes. Net Loss Net loss for the three months ended June 30, 2025, was $1,794,000 compared to $2,045,000 for the same period a year ago. The decrease reflected a reduction of $314,000 in loss from operations and by an increase in interest income of $89,000, partially offset by a decrease in other expenses of $28,000. Net loss for the six months ended June 30, 2025, was $3,821,000 compared to $4,055,000 for the same period a year ago. The decrease reflected a reduction of $436,000 in loss from operations, partially offset by an increase in other expenses of $55,000. Liquidity and Capital Resources The Company expects to incur losses and have negative net cash flows from operating activities as it continues developing its microbial platforms and related products, and as it expands its pipelines and engages in further research and development activities for internal products as well as for its third-party collaborators and licensees. The success of the Company depends on its ability to develop its technologies and products to the point of regulatory approval and subsequent revenue generation or through the sublicensing of the Company’s technologies and products, and its ability to raise capital to finance these developmental efforts. On March 8, 2024, the Company issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 (the “Convertible Notes”) in a private placement. The purchasers of the Convertible Notes included immediate family members and family trusts related to Mark Emalfarb, our Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company’s outstanding common stock, (collectively, the “Purchasers”). The net proceeds from the sale of the Convertible Notes, after deducting offering expenses, were $5,824,000. The Company intends to use the net proceeds from the offering of the Convertible Notes for working capital and general corporate purposes. This private placement funding is expected to support our near-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications. The Convertible Notes are senior, secured obligations of Dyadic and its affiliates, and interest is payable quarterly in cash on the principal amount equal to 8% per annum. The Convertible Notes will mature on March 8, 2027 (the “Maturity Date”), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes. 29 The Convertible Notes can be converted into shares of Dyadic’s common stock, par value $0.001 per share (the “Common Stock”), at the option of the holders of the Convertible Notes (the “Noteholders”) at any time prior to the Maturity Date. On October 4, 2024, the Company entered into an amendment (the “Amendment”) to the Convertible Notes. Pursuant to the Amendment, (i) the conversion price upon which the Convertible Notes will be convertible into shares of the Company’s common stock is $1.40 per share of common stock, and (ii) the Redemption Date (as defined in the Amendment) will fall on any of the 26, 29 and 32-month anniversaries of the original issue date of the Convertible Notes. On May 1, 2025, the Company entered into a second amendment (the “Second Amendment”) to the Convertible Notes. Pursuant to the Second Amendment, the Redemption Date (as defined in the Second Amendment) will now fall on December 1, 2026. During the year ended December 31, 2024, $910,000 of Convertible Notes were converted into 556,623 shares of Common Stock. For more information regarding the Convertible Notes, including the covenants related thereto, see Note 4 to the Consolidated Financial Statements. On July 30, 2025, the Company entered into an underwriting agreement with Craig-Hallum Capital Group LLC, in its capacity as underwriter, relating to the issuance and sale (the “Offering”) of 6,052,000 shares of the Company’s Common Stock. The public offering price in the Offering was $0.95 per share of Common Stock. The closing of the Offering occurred on August 1, 2025. The net proceeds to the Company from the Offering were approximately $5.3 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes, such as product development, sales and marketing The Company expects its existing cash and cash equivalents, and cash raised from the Convertible Notes and the Offering on August 1, 2025, investments in debt securities, and operating cash flows will be sufficient to meet its operational, business, and other liquidity requirements for at least the next twelve (12) months from the date of issuance of the financial statements contained in this Quarterly Report. However, the Company has based this estimate on assumptions that may prove to be wrong, and its operating plan may change as a result of many factors currently unknown to it. In the event our financing needs are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise additional capital through strategic financial opportunities that could include, but are not limited to, future public or private equity offerings, collaboration agreements, and/or other means. Any amounts raised may be used for the further development and commercialization of product candidates, and for other working capital purposes. There is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing shareholders. As of June 30, 2025, cash, cash equivalents, and restricted cash and cash equivalents were $4.0 million compared to $6.5 million as of December 31, 2024. The carrying value of investment grade securities, including accrued interest as of June 30, 2025, was $3.3 million compared to $2.8 million as of December 31, 2024. Additional $5.3 million was received from the net proceeds of the Offering on August 1, 2025 Net cash used in operating activities for the six months ended June 30, 2025 was $2.1 million, which was principally attributable to a net loss of $3.8 million, partially offset by changes in operating assets and liabilities of $1.1 million and share-based compensation expenses of $0.6 million. Net cash used in operating activities for the six months ended June 30, 2024 was $3.1 million, which was principally attributable to a net loss of $4.0 million, partially offset by changes in operating assets and liabilities of $0.4 million and share-based compensation expenses of $0.6 million. Net cash used in investing activities for the six months ended June 30, 2025 was $0.5 million, compared to the net cash used in investing activities of $3.1 million for the six months ended June 30, 2024. The change in investing activities was attributable to a reduction in purchases of investment securities of $0.2 million, an increase in proceeds received from maturities of investment securities of $2.5 million and proceeds from the sale of investment in Alphazyme in 2024 of $0.1 million. Net cash provided by financing activities for the six months ended June 30, 2025 was approximately $24,000, which was related to net proceeds from exercise of stock, compared to the net cash provided by financing activity of $5.8 million for the six months ended June 30, 2024, which was related to net proceeds from the issuance of Convertible Notes. Item 3. Quantitative and Qualitative Disclosures about Market Risk We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective. Changes in Internal Controls Over Financial Reporting There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitation on Effectiveness of Controls A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. 30 PART II Item 1. Legal Proceedings We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. See Note 5 to the Consolidated Financial Statements for commitments and contingencies. Item 1A. Risk Factors Other than as set forth below, there have been no changes to our risk factors from those disclosed in our Annual Report for the 2024 fiscal year filed on March 26, 2025. We have in the past, and may in the future, be unable to comply with the listing standards of the Nasdaq Stock Market LLC (“Nasdaq”). If we fail to comply with listing standards in the future, our common stock may be delisted. Delisting could adversely affect the liquidity of our common stock, and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired. Our common stock is currently listed on the Nasdaq Capital Market, which has minimum requirements that a company must meet in order to remain listed. These requirements include maintaining a minimum Market Value of Listed Securities (“MVLS”) of $35 million, which MVLS cannot fall below $35 million for a period of more than 30 consecutive trading days, or the “MVLS Requirement.” On June 23, 2025, we received a deficiency notice from the Staff of Nasdaq, notifying us that, for the last 30 consecutive business days, the Company’s securities have not maintained the minimum MVLS of $35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2). The MVLS Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until December 20, 2025, to regain compliance with the minimum MVLS requirement by having the Company’s MVLS close at $35 million or more for a minimum of 10 consecutive business days before the MVLS Compliance Date (subject to the Staff’s discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H)). On July 17, 2025, we received a separate deficiency notice from the Staff of Nasdaq notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Minimum Bid Price Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until January 13, 2026 to regain compliance with the minimum bid price requirement by having the Company’s bid price close at $1 per share or more for a minimum of 10 consecutive business days before the Minimum Bid Price Compliance Date (subject to the Staff’s discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H)). If the Company does not regain compliance by the MVLS Compliance Date or the Minimum Bid Price Compliance Date, the Staff will provide written notification that the Company’s common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful. In the event we fail to comply with listing standards in the future, and we do not regain compliance with the MVLS Requirement or the Minimum Bid Price Requirement prior to the expiration of the applicable compliance period, unless Nasdaq exercises its discretion to extend this period, our common stock may be subject to a delisting action by Nasdaq. In the event that our common stock is delisted from Nasdaq as a result of our failure to comply with the MVLS Requirement or the Minimum Bid Price Requirement, as a result of Nasdaq not granting us an extension or the panel not granting us a favorable decision or due to our failure to continue to comply with any other requirement for continued listing on Nasdaq, trading of our common stock could be conducted in the over-the-counter market established for unlisted securities such as the OTCQX, the OTCQB, the OTCID Basic Market or the Pink Limited Market, but there can be no assurance that our common stock will be eligible for trading on any such alternative market. Additionally, if our common stock is delisted from Nasdaq, the liquidity of our common stock would be adversely affected, the market price of our common stock could decrease, our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired and transactions in our common stock could lose federal preemption of state securities laws. Furthermore, there could also be a reduction in our coverage by securities analysts, and the news media and broker-dealers may be deterred from making a market in or otherwise seeking or generating interest in our common stock, which could cause the price of our common stock to decline further. Moreover, delisting may also negatively affect our collaborators’, vendors’, suppliers’ and employees’ confidence in us and employee morale. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults Upon Senior Securities Not applicable. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information (a) None. (b) None. (c) For the quarter ended June 30, 2025, none of our directors or officers (as defined in Section 16 of the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (each as defined in Item 408(a) and (c), respectively, of Regulation S-K). 31 Item 6. Exhibits The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S- K: Incorporated by Reference Exhibit No. Description of Exhibit Form Original No. Date Filed Filed Herewith 3.1 Restated Certificate of Incorporation dated November 1, 2004 10- 12G 3.1 January 14, 2019 3.3 Fourth Amended and Restated Bylaws of Dyadic International, Inc., effective May 29, 2025 8- K 3.1 June 2, 2025 4.1 Second Amendment to Form of Senior Secured Convertible Promissory Note due March 8,2027 8- K 4.1 May 5, 2025 31.1 Certification of Principal Executive Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 x 31.2 Certification of Principal Financial Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 x 32.1 Certification of Principal Executive Officer of Dyadic Pursuant to18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1) 32.2 Certification of Principal Financial Officer of Dyadic Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1) 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101) (1) Furnished herewith. 32 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DYADIC INTERNATIONAL, INC. August 13, 2025 By: /s/ Mark A. Emalfarb Mark A. Emalfarb Chief Executive Officer (Principal Executive Officer) August 13, 2025 By: /s/ Ping W. Rawson Ping W. Rawson Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 33